What are the non‑articular manifestations of hyperuricemia?

Non-Articular Manifestations of Hyperuricemia

Hyperuricemia causes three major non-articular manifestations: urolithiasis (kidney stones), chronic kidney disease progression, and cardiovascular complications, with emerging evidence also documenting ocular involvement and rare soft tissue deposits outside joints.

Renal Manifestations

Urolithiasis (Kidney Stones)

• Uric acid kidney stones occur in patients with hyperuricemia, and urate-lowering therapy provides clear benefit 1
• Both allopurinol and febuxostat lower 24-hour urinary uric acid excretion and reduce stone formation 1
• Among patients with calcium oxalate stones and hyperuricosuria, allopurinol (300 mg/day) significantly reduces the 3-year incidence of stone-related events compared to placebo 1
• Approximately 20% of gout patients develop urinary tract stones 2

Chronic Kidney Disease (CKD)

• Patients with moderate-to-severe CKD (stage ≥3) have higher likelihood of gout progression and clinical tophi development 1
• Interstitial urate nephropathy can develop from chronic hyperuricemia 2
• There may be added benefit of using urate-lowering therapy to prevent progression of renal disease in CKD patients 1
• However, recent evidence shows that routine urate-lowering therapy does not provide clear renoprotective benefit in asymptomatic hyperuricemia with CKD 3

Cardiovascular Manifestations

Association with Cardiovascular Disease

• Elevated serum uric acid is independently associated with cardiovascular mortality, heart failure, stroke, and atherosclerotic disease progression 4, 5
• Strong association exists between hyperuricemia and metabolic syndrome (insulin resistance, hypertension, obesity, dyslipidemia) 2
• Gouty patients often have comorbid coronary artery disease, heart failure, and stroke 2

Mechanistic Pathways

• Hyperuricemia contributes through oxidative stress, endothelial dysfunction, systemic inflammation, and RAAS activation 6, 4
• These mechanisms lead to vascular remodeling and atherosclerotic plaque progression 4

Treatment Considerations

Important caveat: Despite these associations, randomized trials have NOT shown clear cardiovascular benefit from routine urate-lowering therapy in asymptomatic hyperuricemia 6, 5, 3. Addressing cardiovascular issues with guideline-recommended therapies (not urate-lowering drugs) reduces both cardiovascular events and incidentally lowers uric acid 6.

Ocular Manifestations

Tophaceous Deposits

• Monosodium urate crystals can deposit in multiple ocular structures 7:
  • Eyelids
  • Conjunctiva
  • Cornea
  • Iris
  • Sclera
  • Orbit
• Some deposits are asymptomatic and found incidentally; others cause symptoms 7

Inflammatory Ocular Conditions

• Dry eye syndrome
• Red eye
• Uveitis
• Intraocular hypertension and glaucoma
• Cataracts 7

Soft Tissue Involvement Beyond Joints

Tophi in Non-Articular Locations

• Subcutaneous tophi can develop in various tissues including tendons, bursae, and nerves 8
• Common locations include helix of the ear, olecranon bursa, and over interphalangeal joints 2
• Rare involvement of forearm extensor tendons has been documented 8
• Development is related to both degree and duration of hyperuricemia 2

Cutaneous Manifestations

• Disseminated chronic tophaceous gout presents as a spectrum 8:
  • Classical nodular tophi
  • Miliarial gout
  • Panniculitis
  • Ulcerative cutaneous gout

Clinical Decision Algorithm

When to initiate urate-lowering therapy for non-articular manifestations 1:

1. Strong indication (conditionally recommended):

   • First gout flare WITH urolithiasis → Initiate ULT
   • First gout flare WITH CKD stage ≥3 → Initiate ULT
   • First gout flare WITH serum urate >9 mg/dl → Initiate ULT

2. NOT recommended:

   • Asymptomatic hyperuricemia alone (even with CKD, CVD, urolithiasis, or hypertension) → Do NOT initiate ULT 1
   • The number needed to treat is 24 patients for 3 years to prevent a single incident gout flare 1
   • Major guideline consensus (ACR, EULAR, KDIGO) recommends against pharmacologic treatment of asymptomatic hyperuricemia 3

Critical Pitfalls to Avoid

• Do not treat asymptomatic hyperuricemia solely for cardiovascular or renal "protection" - the evidence does not support this practice despite epidemiological associations 6, 5, 3
• Do not overlook urolithiasis history when deciding on ULT - this is a clear indication for treatment 1
• Do not assume all elevated uric acid requires treatment - focus on symptomatic disease or specific high-risk features 1
• Remember that optimizing cardiovascular risk factors with standard therapies (antihypertensives, statins, etc.) will lower uric acid and improve outcomes better than targeting uric acid directly in asymptomatic patients 6